Fidaxomicin is a macrolide antibacterial medicine administered orally for the treatment of Clostridioides difficile-associated diarrhea (CDAD), an intestinal infection caused by toxin-producing C. difficile. It has a distinctive, relatively narrow spectrum of antibacterial activity and is minimally absorbed systemically after oral administration, allowing it to act primarily within the gastrointestinal tract where the infection occurs.

Fidaxomicin works by inhibiting bacterial RNA polymerase, thereby interfering with bacterial RNA synthesis and preventing the growth and reproduction of C. difficile. Its activity against C. difficile, together with its limited systemic absorption, makes it particularly suited to the treatment of this intestinal infection.

The medicine is available as 200 mg tablets and, in certain products, as an oral suspension. For adults, the standard tablet regimen is 200 mg orally twice daily for 10 days, and it may be taken with or without food.

Fidaxomicin should be used only when C. difficile infection is proven or strongly suspected. It is not intended for the treatment of infections caused by other bacteria, and unnecessary use of antibacterial medicines can contribute to antimicrobial resistance.

• Treatment of Clostridioides difficile-associated diarrhea (CDAD) in adults.
• Treatment of CDAD in pediatric patients 6 months of age and older when using an appropriately approved fidaxomicin product.
• Management of intestinal infection caused by susceptible C. difficile when treatment with an appropriate antibacterial agent is clinically indicated.
• Reducing the risk of recurrent C. difficile infection compared with some alternative antibacterial treatment approaches, particularly because of its targeted activity and relatively limited disruption of the normal intestinal microbiota. Clinical treatment decisions should be made by the healthcare provider.

Important: Fidaxomicin should not be used to treat infections other than C. difficile-associated diarrhea, because its minimal systemic absorption makes it unsuitable for most infections outside the gastrointestinal tract.

Fidaxomicin produces its therapeutic effect primarily within the gastrointestinal tract by inhibiting bacterial RNA polymerase, an enzyme essential for bacterial RNA synthesis.

• Inhibition of growth and reproduction of C. difficile.
• Reduction of toxin-producing bacterial activity within the intestine.
• Control of C. difficile-associated diarrhea and associated gastrointestinal symptoms.
• Eradication or suppression of susceptible C. difficile from the intestinal tract.
• Limited systemic exposure, because fidaxomicin is minimally absorbed following oral administration.
• Preservation of much of the normal intestinal microbiota compared with broader-spectrum antibacterial therapies, which may contribute to its clinical utility in CDAD.

Fidaxomicin's narrow antibacterial spectrum and intestinal activity make it particularly suitable for treating C. difficile infection while limiting unnecessary systemic antibacterial exposure.

It is important to understand that improvement in diarrhea does not necessarily mean that the underlying infection should be considered cured immediately. Patients should complete the prescribed course unless their healthcare provider instructs them otherwise.

Fidaxomicin should be taken exactly as prescribed by the healthcare provider.

Adults:

The usual recommended adult dosage is

Fidaxomicin 200 mg orally twice daily for 10 days.

Administration:

• Take the tablet orally.
• It may be taken with or without food.
• Swallow the tablet whole with sufficient water.
• Take the doses at approximately 12-hour intervals, unless otherwise instructed.
• Complete the entire prescribed course even if diarrhea improves before treatment is finished.

If You Miss a Dose:

• Take the missed dose when you remember, unless it is almost time for the next scheduled dose.
• Do not take two doses at the same time to compensate for a missed dose.

If Symptoms Improve:

Do not stop treatment early unless instructed by your healthcare provider. Completing the prescribed course helps maximize treatment effectiveness and reduces the risk of treatment failure and antimicrobial resistance.

Pediatric Use:

Approved fidaxomicin formulations may be used in children 6 months of age and older, with dosing determined according to the specific formulation, age, and/or body weight. Pediatric dosing should be prescribed by a healthcare professional.

Common:

• Nausea
• Vomiting
• Abdominal pain
• Gastrointestinal hemorrhage
• Anemia
• Neutropenia

Some patients may also experience gastrointestinal discomfort or changes in bowel symptoms during treatment.

Serious:

Hypersensitivity / Allergic Reactions

Serious hypersensitivity reactions have been reported.

Seek immediate medical attention if you experience:

• Swelling of the face, lips, tongue, or throat
• Difficulty breathing
• Severe itching
• Widespread rash
• Sudden dizziness or fainting

If a severe hypersensitivity reaction occurs, fidaxomicin should be discontinued.

Gastrointestinal Bleeding:

Gastrointestinal hemorrhage has been reported among adverse reactions. Patients should promptly report:

• Blood in stools
• Black or tarry stools
• Vomiting blood
• Persistent abdominal pain

Persistent or Worsening Diarrhea:

If diarrhea does not improve or becomes significantly worse during or after treatment, contact your healthcare provider. Persistent symptoms may require reassessment of the diagnosis and treatment.

Fidaxomicin has minimal systemic absorption, and therefore clinically significant drug interactions are relatively limited. However, certain medicines may affect the intestinal or systemic exposure to fidaxomicin.

Cyclosporine

Cyclosporine may increase fidaxomicin and its active metabolite exposure because of effects on intestinal transporters such as P-glycoprotein (P-gp).

If fidaxomicin is administered with cyclosporine, the healthcare provider should consider the potential for increased exposure and monitor the patient appropriately.

Other Medicines

Patients should inform their healthcare provider about all medicines they are taking, including:

• Prescription medicines
• Over-the-counter medicines
• Vitamins
• Herbal products
• Dietary supplements

Although fidaxomicin has relatively few clinically important drug interactions, the complete medication history should be reviewed before treatment.

Important Advice

Do not start, stop, or change any medication without consulting your healthcare provider.

• Store at controlled room temperature according to the manufacturer's labeled storage requirements.
• Keep the tablets in their original container until use.
• Protect the medicine from excessive moisture and heat.
• Keep the container tightly closed.
• Keep out of the reach and sight of children.
• Do not use the medicine after the expiry date printed on the package.
• Dispose of expired or unused medicine according to local pharmaceutical-waste disposal recommendations.

Fidaxomicin is a narrow-spectrum intestinal antibacterial specifically designed for C. difficile-associated diarrhea. Its minimal systemic absorption and targeted activity make it an important treatment option for appropriately diagnosed CDAD. Correct diagnosis, adherence to the prescribed course, adequate hydration, and prompt recognition of recurrent or worsening symptoms are essential for optimal treatment outcomes.